Hsu YC - Search Results

1

Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study).

Hirode G, Hansen BE, Chen CH, Su TH, Wong GLH, Seto WK, d'Almeida AF, Papatheodoridi M, Brakenhoff SM, Lens S, Choi HSJ, Chien RN, Feld JJ, Forns X, Sonneveld MJ, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Chan HLY, Kao JH, Hsu YC, Cornberg M, Jeng WJ, Janssen HLA; RETRACT-B study group. Hirode G, et al. Among authors: hsu yc. Am J Gastroenterol. 2024 Apr 22. doi: 10.14309/ajg.0000000000002759. Online ahead of print. Am J Gastroenterol. 2024. PMID: 38483300

2

Primary biliary cirrhosis associated with pernicious anemia.

Chung CS, Hsu YC, Huang SY, Jeng YM, Chen CH. Chung CS, et al. Among authors: hsu yc. Can Fam Physician. 2010 Sep;56(9):889-91. Can Fam Physician. 2010. PMID: 20841590 Free PMC article. No abstract available.

3

Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen-Negative Patients.

Hsu YC, Mo LR, Chang CY, Wu MS, Kao JH, Wang WL, Yang TH, Wang CS, Chiang MF, Chen CC, Fang YJ, Hung HW, Wu CY, Lin JT. Hsu YC, et al. Clin Gastroenterol Hepatol. 2016 Oct;14(10):1490-1498.e3. doi: 10.1016/j.cgh.2016.03.024. Epub 2016 Mar 24. Clin Gastroenterol Hepatol. 2016. PMID: 27018299

4

Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy.

Hsu YC, Mo LR, Chang CY, Wu MS, Yang TH, Kao JH, Chen CC, Tseng CH, Tai CM, Lin CW, Wu CY, Lin JT. Hsu YC, et al. J Gastroenterol Hepatol. 2017 Aug;32(8):1512-1519. doi: 10.1111/jgh.13728. J Gastroenterol Hepatol. 2017. PMID: 28122151

5

Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B.

Lee TY, Hsu YC, Yu SH, Lin JT, Wu MS, Wu CY. Lee TY, et al. Among authors: hsu yc. Clin Gastroenterol Hepatol. 2018 Jun;16(6):947-954.e4. doi: 10.1016/j.cgh.2017.09.031. Epub 2017 Sep 22. Clin Gastroenterol Hepatol. 2018. PMID: 28951229

6

Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy.

Chien NH, Huang YT, Wu CY, Chang CY, Wu MS, Kao JH, Mo LR, Tai CM, Lin CW, Yang TH, Lin JT, Hsu YC. Chien NH, et al. Among authors: hsu yc. BMC Gastroenterol. 2017 Dec 8;17(1):154. doi: 10.1186/s12876-017-0697-3. BMC Gastroenterol. 2017. PMID: 29221441 Free PMC article.

7

Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B.

Tseng CH, Hsu YC, Chang CY, Tseng TC, Wu MS, Lin JT, Kao JH. Tseng CH, et al. Among authors: hsu yc. J Formos Med Assoc. 2018 Oct;117(10):915-921. doi: 10.1016/j.jfma.2017.11.012. Epub 2017 Dec 15. J Formos Med Assoc. 2018. PMID: 29249417 Free article.

8

Letter to the Editor: Deliberations More Than a Cut-off Hepatitis B Surface Antigen Value for Nucleos(t)ide Analogue Cessation.

Jeng WJ, Hsu YC, Su TH, Chen CH. Jeng WJ, et al. Among authors: hsu yc. Hepatology. 2019 Oct;70(4):1488-1489. doi: 10.1002/hep.30576. Hepatology. 2019. PMID: 30793771 No abstract available.

9

Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be Done.

Hsu YC, Tseng CH, Kao JH. Hsu YC, et al. Clin Gastroenterol Hepatol. 2019 Apr;17(5):1000-1001. doi: 10.1016/j.cgh.2018.09.002. Clin Gastroenterol Hepatol. 2019. PMID: 30902225 No abstract available.

10

Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium.

Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH; REAL-C Investigators. Huang CF, et al. Among authors: hsu yc. Hepatol Int. 2019 Sep;13(5):587-598. doi: 10.1007/s12072-019-09974-z. Epub 2019 Aug 28. Hepatol Int. 2019. PMID: 31463665

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,457 results

Search Page